Send me a link:

*Text messaging rates may apply.

 Dow Down0.72% Nasdaq Down0.50%

GW Pharmaceuticals plc (GWPH)

-NasdaqGM
84.88 Down 2.09(2.40%) Jul 25, 4:00PM EDT
|After Hours : 84.49 Down 0.39 (0.46%) Jul 25, 7:51PM EDT
ProfileGet Profile for:
GW Pharmaceuticals plc
Porton Down Science Park
Salisbury, SP4 0JQ
United Kingdom - Map
Phone: 44 19 8055 7000
Fax: 44 19 8055 7111
Website: http://www.gwpharm.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Major
Full Time Employees:207

Business Summary 

GW Pharmaceuticals plc, a biopharmaceutical company, together with its subsidiaries, is engaged in discovering, developing, and commercializing cannabinoid prescription medicines. The company operates through three segments: Sativex Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on GW Pharmaceuticals plc

Key Executives 
 PayExercised
Dr. Geoffrey W. Guy BSc, MB BS, MRCS Eng, LRCP, LMSSA. Dip Pharm Med, 59
Founder, Exec. Chairman and Chairman of Nominations Committee
902.00K0.00
Mr. Justin D. Gover BSc,MBA, 43
Chief Exec. Officer, Managing Director and Exec. Director
735.00K0.00
Mr. Adam David George BSc, ACA, 44
Chief Financial Officer, Principal Accounting Officer, Company Sec. and Exec. Director
395.00K0.00
Mr. Christopher John Tovey BSc, 48
Chief Operating Officer and Exec. Director
461.00K0.00
Dr. Stephen Wright MA, M.D., FRCP (Edin), FFPM., 62
R&D Director and Exec. Director
625.00K0.00
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.